NANOGEN

One Dose To Cure Type 2 Diabetes

Learn more
530

million people have type II diabetes
in 2019

2

million deaths due to type II diabetes in 2019

7x

estimated increase in type II patients by 2060

26.7bn

market size of type-2 diabetes as of March 2021

Our proposition

Our idea will revolutionise the treatment of type II diabetes

Problem
Type 2 diabetes is the most common form of diabetes.
‍
Your body can't use the insulin it makes as well as it should.

It affects more than 34 million people in the United States, or about 10% of the population.

Type 2 diabetes is more likely to develop in people who are overweight or obese. It also has a ton of severe after effects.
Solution
MOF 16 nanoparticle, to deliver a gene therapy approach via the bloodstream.

Our solution works by targeting the SLC2A4 gene and upregulating GLUT  4 using a CRISPR activator.

By upregulating GLUT 4, we aim to increase the uptake of glucose into cells and reverse insulin resistance.
Impact
Around 530 million people around the world are affected by type 2 diabetes, that's around 8% of the world population.

What if we could deliver a treatment that can reverse insulin resistance and provide lasting effects for type 2 diabetics?

Well, that's exactly what we are doing at NanoGen. One cure, one dose.
Delivery System

Novel MOF Delivery System

Using MOF-16, we can harness the large surface area and high programmability to our advantage to deliver the CRISPR activator to the adipose tissue in the body.

Learn More
CRISPR activator

Overproducing the protein GLUT-4

By modifying the gene SLC2A4 with a tailored mRNA sequence using CRISPR, we can regulate the GLUT-4 protein, and if we overproduce it, insulin resistance reverses.

Learn More
One permanent dose

A tailored injection of our solution

Our injection dose is a permanent fix to diabetes, it would contain our MOF-16 nanorobots that would contain our CRISPR activator and would be programmed to target the adipose tissue

Learn More

Efficient

Due to a targeted approach of the solution, and the single use aim of the product. It is very unique and accessible to users.

Permanent

Compared to 99% of this industry, we hope to make this a permanent fix. This is done by specifically modifying every SLC2A4 gene.

Breakthrough

Our solution contains major breakthrough concepts like using MOF technologies as well as nano-biodegradable microchips.

Existing Solutions


Efficiency
‍

Permanent Fix
‍

Impact
‍

The bold ideas proposed by NanoGen aim to offer a holy grail cure for type 2 diabetes (T2D). SLC2A4 is known to be associated with genetic susceptibility of T2D (and is also reported to be associated with insulin resistance as well). Activation of SLC2A4 is likely to have an effect on GLUT4, and its downstream effects on T2D need to be studied in vitro and in vivo animal models. Despite these challenges, this project presents a breakthrough approach for T2D and its potential needs be explored further.

Parthiban Vijayarangakannan

CEO of Svastia Genetics

This is an amazing proposal to cure very complex disease, diabetes by modulating therapeutic targets of the disease. Team chooses cutting edge pharmacological interventional strategies - CRISPR gene editing technology and novel drug delivery, nanotechnology platform as a potential cure for diabetes. Although it is challenging, this proposal drives the promising novel modality for the future drug development to manifest diabetes treatment. Looking forward to the proposal advancement.

Anonymous

Research Scientist at AstraZeneca

Meet the team

Vivek Kommi
Vivek is passionate about using nanotech and quantum computing to revolutionalize the industry of drug delivery by creating new simulation methods for novel nanocarriers. He has also worked on several consulting projects for multi-billion dollar companies, for example, Walmart Blue Labs, Amazon Alexa, and PA
Viola Seda
Viola is passionate about climate tech and solar energy, and has previously worked on creating a new encapsulation layer for perovskite solar cells. She has also worked as a problem-solver and consultant alongside Walmart BlueLabs and Amazon Alexa, and led a successful campaign to ban single-use plastic foodware in her county.
Abhilash Mohapatra
Abhilash is an innovative space and health tech enthusiast working on redesigning parts for Terran 1 at Relativity Space. He collaborates with companies like Amazon Alexa and Ikea to align products with Gen Z values. With a drive for impactful change, Abhilash seeks new challenges to make a difference.
Naina Kumar
Naina is a machine learning, health tech, and human longevity enthusiast. She has previously worked on creating an LSTM to predict r- peaks in ECG signals and a microloans and entrepreneurship program for university students in Ghana. Also, she worked alongside Mastercard Foundation, Deloitte, and Walmart Blue Labs.
ArticleOne PagerPresentationVideoCopyright @2023